A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy

Trial Profile

A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Jul 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Nivolumab (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 28 Jun 2017 Planned End Date changed from 30 Oct 2020 to 1 Oct 2020.
    • 28 Jun 2017 Planned primary completion date changed from 30 Nov 2017 to 1 Nov 2017.
    • 27 Jun 2017 Planned number of patients changed from 60 to 92.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top